Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Open-Label Multiple Ascending Dose Study of INZ-701 With a Long-Term Extension in Adults With ABCC6 Deficiency Manifesting as Pseudoxanthoma Elasticum (PXE)

NCT05030831 is registered in ClinicalTrials.gov with Inozyme Pharma as lead sponsor.

NCT NCT05030831
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05030831 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Open-Label Multiple Ascending Dose Study of INZ-701 With a Long-Term Extension in Adults With ABCC6 Deficiency Manifesting as Pseudoxanthoma Elasticum (PXE)
Lead sponsor
Inozyme Pharma
Phase
Phase 1/2
Overall status
Completed
Start date
April 11, 2022
Completion date
July 9, 2024
Enrollment
10 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

atp-binding cassette subfamily c member 6 deficiency, generalized arterial calcification of infancy, pseudoxanthoma elasticum